Previous 10 | Next 10 |
Global Blood Therapeutics (NASDAQ: GBT ) : Q2 GAAP EPS of -$0.86 beats by $0.29 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Achieved Oxbryta ® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions Announced plans to seek approval of Oxbryta for younger pediatric patients in the United States and seek approval of Oxbryta in Europe ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SOUTH SAN FRANCISCO, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences: William Blair Biotech Focus C...
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, after U.S. financial markets close. Management will host a conferenc...
Investing in innovative drugs and therapies that treat patients with highly unmet medical needs can be a rewarding venture. Indeed, year to date, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has returned nearly 20%. During the same period, the S&P 500 index has gained just 1...
SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell disease (SCD) community have been awarded a total of $250,000 through the company’s 2020...
Global Blood Therapeutics (NASDAQ: GBT ) intends to submit a marketing application in Europe seeking approval to use Oxbryta (voxelotor) to treat hemolytic anemia in patients at least 12 years old with sickle cell disease (SCD). It expects to complete the filing by mid-2021. More news on...
Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (G...
BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective imme...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...